Phaseline

Companies › MapLight Therapeutics

MapLight Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 2; Psychiatry, Neurology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ML-004–Phase 2Autism Spectrum DisorderNov 2027
ML-007C-MA–Phase 2Psychosis Associated With Alzheimer's Disease; SchizophreniaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05889273ML-004Phase 2Autism Spectrum DisorderPsychiatryNov 2027
NCT06887192ML-007C-MAPhase 2Psychosis Associated With Alzheimer's DiseaseNeurologyDec 2027
NCT07459647ML-007C-MAPhase 2SchizophreniaPsychiatryFeb 2030

From the company's SEC filings

Cash and short-term investments of $305m on 2026-06-30; operating cash outflow about $195m a year; runway about 19 months at that burn, to Jan 2028; 2 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Spinogenix Shanghai Auzone Biological Technology Reviva Pharmaceuticals Noema Pharma Bazelet Nehushtan

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.